yten-20210630
000112170212/312021Q2FALSE0.0250.0250.02500011217022021-01-012021-06-30xbrli:shares00011217022021-08-10iso4217:USD00011217022021-06-3000011217022020-12-31iso4217:USDxbrli:shares0001121702us-gaap:GrantMember2021-04-012021-06-300001121702us-gaap:GrantMember2020-04-012020-06-300001121702us-gaap:GrantMember2021-01-012021-06-300001121702us-gaap:GrantMember2020-01-012020-06-3000011217022021-04-012021-06-3000011217022020-04-012020-06-3000011217022020-01-012020-06-3000011217022019-12-3100011217022020-06-300001121702us-gaap:SeriesBPreferredStockMember2021-03-310001121702us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-03-310001121702us-gaap:CommonStockMember2021-03-310001121702us-gaap:AdditionalPaidInCapitalMember2021-03-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001121702us-gaap:RetainedEarningsMember2021-03-3100011217022021-03-310001121702us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001121702us-gaap:CommonStockMember2021-04-012021-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001121702us-gaap:RetainedEarningsMember2021-04-012021-06-300001121702us-gaap:SeriesBPreferredStockMember2021-06-300001121702us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-06-300001121702us-gaap:CommonStockMember2021-06-300001121702us-gaap:AdditionalPaidInCapitalMember2021-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001121702us-gaap:RetainedEarningsMember2021-06-300001121702us-gaap:SeriesBPreferredStockMember2020-03-310001121702us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-03-310001121702us-gaap:CommonStockMember2020-03-310001121702us-gaap:AdditionalPaidInCapitalMember2020-03-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001121702us-gaap:RetainedEarningsMember2020-03-3100011217022020-03-310001121702us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001121702us-gaap:CommonStockMember2020-04-012020-06-300001121702us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-04-012020-06-300001121702us-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMember2020-04-012020-06-300001121702us-gaap:SeriesAPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001121702us-gaap:RetainedEarningsMember2020-04-012020-06-300001121702us-gaap:SeriesBPreferredStockMember2020-06-300001121702us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-06-300001121702us-gaap:CommonStockMember2020-06-300001121702us-gaap:AdditionalPaidInCapitalMember2020-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001121702us-gaap:RetainedEarningsMember2020-06-300001121702us-gaap:SeriesBPreferredStockMember2020-12-310001121702us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-12-310001121702us-gaap:CommonStockMember2020-12-310001121702us-gaap:AdditionalPaidInCapitalMember2020-12-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001121702us-gaap:RetainedEarningsMember2020-12-310001121702us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001121702us-gaap:CommonStockMember2021-01-012021-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001121702us-gaap:RetainedEarningsMember2021-01-012021-06-300001121702us-gaap:SeriesBPreferredStockMember2019-12-310001121702us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-12-310001121702us-gaap:CommonStockMember2019-12-310001121702us-gaap:AdditionalPaidInCapitalMember2019-12-310001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001121702us-gaap:RetainedEarningsMember2019-12-310001121702us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001121702us-gaap:CommonStockMember2020-01-012020-06-300001121702yten:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-06-300001121702yten:SeriesAConvertiblePreferredStockMemberus-gaap:CommonStockMember2020-01-012020-06-300001121702us-gaap:AdditionalPaidInCapitalMemberyten:SeriesAConvertiblePreferredStockMember2020-01-012020-06-300001121702yten:SeriesBConvertiblePreferredStockMemberus-gaap:CommonStockMember2020-01-012020-06-300001121702us-gaap:AdditionalPaidInCapitalMemberyten:SeriesBConvertiblePreferredStockMember2020-01-012020-06-300001121702us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001121702us-gaap:RetainedEarningsMember2020-01-012020-06-30xbrli:pure0001121702us-gaap:AccountsReceivableMemberyten:MichiganStateUniversityMemberus-gaap:GrantMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001121702us-gaap:AccountsReceivableMemberyten:MichiganStateUniversityMemberus-gaap:GrantMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001121702yten:MichiganStateUniversityMemberus-gaap:GrantMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300001121702yten:MichiganStateUniversityMemberus-gaap:GrantMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001121702us-gaap:GrantMemberyten:CanadianIndustrialResearchAssistanceProgramMember2021-01-012021-03-310001121702us-gaap:GrantMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberyten:CanadianIndustrialResearchAssistanceProgramMember2021-01-012021-06-300001121702yten:MichiganStateUniversityMemberus-gaap:GrantMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300001121702yten:MichiganStateUniversityMemberus-gaap:GrantMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300001121702us-gaap:GrantMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberyten:CanadianIndustrialResearchAssistanceProgramMember2020-04-012020-06-300001121702us-gaap:GrantMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberyten:CanadianIndustrialResearchAssistanceProgramMember2020-01-012020-06-300001121702us-gaap:GrantMemberyten:CanadianIndustrialResearchAssistanceProgramMember2020-04-012020-06-300001121702us-gaap:GrantMemberyten:CanadianIndustrialResearchAssistanceProgramMember2020-01-012020-06-30yten:segment0001121702us-gaap:EquipmentMember2021-01-012021-06-300001121702us-gaap:FurnitureAndFixturesMember2021-01-012021-06-300001121702us-gaap:ComputerSoftwareIntangibleAssetMember2021-01-012021-06-3000011217022020-01-152020-01-150001121702yten:EmployeeAndDirectorsStockOptionsMember2021-04-012021-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2020-04-012020-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2021-01-012021-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2020-01-012020-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2020-04-012020-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesAConvertiblePreferredStockMember2021-04-012021-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesAConvertiblePreferredStockMember2020-04-012020-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesAConvertiblePreferredStockMember2021-01-012021-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesAConvertiblePreferredStockMember2020-01-012020-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesBConvertiblePreferredStockMember2021-04-012021-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesBConvertiblePreferredStockMember2020-04-012020-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesBConvertiblePreferredStockMember2021-01-012021-06-300001121702us-gaap:ConvertiblePreferredStockMemberyten:SeriesBConvertiblePreferredStockMember2020-01-012020-06-300001121702us-gaap:WarrantMember2021-04-012021-06-300001121702us-gaap:WarrantMember2020-04-012020-06-300001121702us-gaap:WarrantMember2021-01-012021-06-300001121702us-gaap:WarrantMember2020-01-012020-06-300001121702us-gaap:USTreasuryAndGovernmentMember2021-06-300001121702us-gaap:USTreasuryAndGovernmentMember2020-12-310001121702us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueMeasurementsRecurringMember2021-06-300001121702us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001121702us-gaap:FairValueMeasurementsRecurringMember2020-12-3100011217022020-01-150001121702us-gaap:EmployeeStockOptionMember2021-06-300001121702us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2020-12-310001121702yten:EmployeeAndDirectorsStockOptionsMember2021-01-012021-06-300001121702yten:EmployeeAndDirectorsStockOptionsMember2021-06-3000011217022021-01-012021-01-0100011217022021-05-242021-05-240001121702us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001121702us-gaap:RestrictedStockUnitsRSUMember2020-12-310001121702us-gaap:RestrictedStockUnitsRSUMember2021-06-30utr:sqft0001121702yten:PresidentialWayWoburnMassachusettsMember2020-02-290001121702yten:PresidentialWayWoburnMassachusettsMember2016-10-012016-10-310001121702yten:PresidentialWayWoburnMassachusettsMemberyten:CJCheilJedangCorporationMember2016-10-310001121702yten:SixHundredFiftySuffolkStreetLowellMassachusettsMember2021-06-300001121702yten:A410DowneyRoadAnd110GymnasiumPlaceMember2021-06-300001121702yten:PaycheckProtectionProgramLoanMember2020-04-012020-04-300001121702yten:PaycheckProtectionProgramLoanMember2020-04-012020-06-300001121702yten:PaycheckProtectionProgramLoanMember2020-01-012020-06-300001121702us-gaap:CollaborativeArrangementMember2020-11-120001121702us-gaap:CollaborativeArrangementMember2020-11-122020-11-120001121702us-gaap:CollaborativeArrangementMember2021-06-300001121702us-gaap:OperatingSegmentsMembercountry:US2021-04-012021-06-300001121702us-gaap:OperatingSegmentsMembercountry:CA2021-04-012021-06-300001121702us-gaap:OperatingSegmentsMember2021-04-012021-06-300001121702srt:GeographyEliminationsMembercountry:CA2021-04-012021-06-300001121702srt:GeographyEliminationsMember2021-04-012021-06-300001121702country:US2021-04-012021-06-300001121702country:CA2021-04-012021-06-300001121702us-gaap:OperatingSegmentsMembercountry:US2020-04-012020-06-300001121702us-gaap:OperatingSegmentsMembercountry:CA2020-04-012020-06-300001121702us-gaap:OperatingSegmentsMember2020-04-012020-06-300001121702srt:GeographyEliminationsMembercountry:CA2020-04-012020-06-300001121702srt:GeographyEliminationsMember2020-04-012020-06-300001121702country:US2020-04-012020-06-300001121702country:CA2020-04-012020-06-300001121702us-gaap:OperatingSegmentsMembercountry:US2021-01-012021-06-300001121702us-gaap:OperatingSegmentsMembercountry:CA2021-01-012021-06-300001121702us-gaap:OperatingSegmentsMember2021-01-012021-06-300001121702srt:GeographyEliminationsMembercountry:CA2021-01-012021-06-300001121702srt:GeographyEliminationsMember2021-01-012021-06-300001121702country:US2021-01-012021-06-300001121702country:CA2021-01-012021-06-300001121702us-gaap:OperatingSegmentsMembercountry:US2020-01-012020-06-300001121702us-gaap:OperatingSegmentsMembercountry:CA2020-01-012020-06-300001121702us-gaap:OperatingSegmentsMember2020-01-012020-06-300001121702srt:GeographyEliminationsMembercountry:CA2020-01-012020-06-300001121702srt:GeographyEliminationsMember2020-01-012020-06-300001121702country:US2020-01-012020-06-300001121702country:CA2020-01-012020-06-300001121702country:USsrt:ReportableGeographicalComponentsMember2021-06-300001121702country:CAsrt:ReportableGeographicalComponentsMember2021-06-300001121702srt:GeographyEliminationsMember2021-06-300001121702country:USsrt:ReportableGeographicalComponentsMember2020-12-310001121702country:CAsrt:ReportableGeographicalComponentsMember2020-12-310001121702srt:GeographyEliminationsMember2020-12-310001121702yten:PublicOfferingMember2021-02-032021-02-030001121702yten:PublicOfferingMember2021-02-030001121702yten:PublicOfferingMember2020-08-262020-08-260001121702yten:PublicOfferingMember2020-08-260001121702us-gaap:PrivatePlacementMember2020-08-262020-08-260001121702us-gaap:PrivatePlacementMember2020-08-2600011217022019-11-192019-11-190001121702yten:PublicOfferingAndPrivatePlacementMember2019-11-192019-11-1900011217022019-11-190001121702us-gaap:CommonStockMember2020-01-152020-01-1500011217022019-01-012019-12-310001121702yten:ClassBUnitsMemberyten:PublicOfferingMember2019-11-192019-11-190001121702yten:SeriesAWarrantMemberyten:ClassBUnitsMember2019-11-190001121702yten:SeriesBWarrantMember2019-11-190001121702yten:SeriesAConvertiblePreferredStockMember2021-06-300001121702us-gaap:CommonStockMember2020-04-300001121702yten:PublicOfferingMemberyten:SeriesAWarrantExpiringMay2022Member2021-06-300001121702yten:PublicOfferingMemberyten:SeriesBWarrantExpiringMay2027Member2021-06-300001121702us-gaap:PrivatePlacementMemberyten:SeriesAWarrantExpiringMay2022Member2021-06-300001121702yten:SeriesBWarrantExpiringMay2027Memberus-gaap:PrivatePlacementMember2021-06-300001121702yten:PublicOfferingMemberyten:SeriesAWarrantExpiringDecember2022Member2021-06-300001121702yten:WarrantExpiringJanuary2024Member2021-06-300001121702yten:WarrantExpiringSeptember2024Member2021-06-300001121702us-gaap:CommonStockMember2020-02-012020-02-2900011217022020-02-290001121702us-gaap:EmployeeStockOptionMember2020-12-310001121702us-gaap:WarrantMember2021-06-300001121702us-gaap:WarrantMember2020-12-310001121702yten:TephaIncMember2002-12-310001121702yten:TephaIncMemberyten:LicenseFeesMember2002-01-012002-12-310001121702yten:TephaIncMemberus-gaap:SubsequentEventMember2021-07-262021-07-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended June 30, 2021

OR

      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                to                
Commission file number 001-33133
YIELD10 BIOSCIENCE, INC.
Delaware04-3158289
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
19 Presidential Way
Woburn, MA
01801
(Address of principal executive offices)(Zip Code)
(617) 583-1700
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockYTEN
The Nasdaq Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ý  No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý  No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” "accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated filerý Smaller reporting companyý
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No ý

The number of shares outstanding of the registrant’s common stock as of August 10, 2021 was 4,871,323.

1


Yield10 Bioscience, Inc.
Form 10-Q
For the Quarter Ended June 30, 2021

Table of Contents

Page
Item
Item

2


PART I.  FINANCIAL INFORMATION
ITEM 1.  CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(in thousands, except share and per share data)

June 30,
2021
December 31,
2020
Assets
Current Assets:
Cash and cash equivalents$15,641 $3,423 
Short-term investments4,921 6,279 
Accounts receivable76 86 
Unbilled receivables38 27 
Prepaid expenses and other current assets509 527 
Total current assets21,185 10,342 
Restricted cash264 264 
Property and equipment, net949 921 
Right-of-use assets2,537 2,712 
Other assets275 283 
Total assets$25,210 $14,522 
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable$101 $60 
Accrued expenses1,237 1,297 
Lease liabilities485 457 
Total current liabilities1,823 1,814 
Lease liabilities, net of current portion2,915 3,163 
Other long-term liabilities10 13 
Total liabilities4,748 4,990 
Commitments and contingencies (Note 10)
Stockholders’ Equity:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding
  
Common stock ($0.01 par value per share); 60,000,000 shares authorized at June 30, 2021 and December 31, 2020; 4,868,466 and 3,334,048 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively
49 33 
Additional paid-in capital401,319 384,758 
Accumulated other comprehensive loss(153)(159)
Accumulated deficit(380,753)(375,100)
Total stockholders’ equity20,462 9,532 
Total liabilities and stockholders’ equity$25,210 $14,522 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
3


YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(in thousands, except share and per share data)
Three Months Ended
June 30,
Six Months Ended
June 30,
2021202020212020
Revenue:
Grant revenue$174 $221 $370 $400 
Total revenue174 221 370 400 
Expenses:
Research and development1,651 1,179 2,967 2,639 
General and administrative1,604 1,179 3,036 2,566 
Total expenses3,255 2,358 6,003 5,205 
Loss from operations(3,081)(2,137)(5,633)(4,805)
Other income (expense):
Change in fair value of warrants   (957)
Loan forgiveness income (Note 9) 333  333 
Other income (expense), net 15 (1)48 
Total other income (expense) 348 (1)(576)
Net loss from operations before income taxes(3,081)(1,789)(5,634)(5,381)
Income tax provision(11)(7)(19)(15)
Net loss$(3,092)$(1,796)$(5,653)$(5,396)
Basic and diluted net loss per share$(0.64)$(0.92)$(1.23)$(2.95)
Number of shares used in per share calculations:
Basic and diluted4,868,156 1,957,927 4,583,723 1,827,526 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
4


YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
UNAUDITED
(in thousands)

Three Months Ended
June 30,
Six Months Ended
   June 30,
2021202020212020
Net loss:$(3,092)$(1,796)$(5,653)$(5,396)
Other comprehensive loss
Change in unrealized gain on investments (15)1 7 
Change in foreign currency translation adjustment6 7 5 (48)
Total other comprehensive income (loss)6 (8)6 (41)
Comprehensive loss$(3,086)$(1,804)$(5,647)$(5,437)

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
5


YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
UNAUDITED
(in thousands)

Six Months Ended
   June 30,
 20212020
Cash flows from operating activities  
Net loss$(5,653)$(5,396)
Adjustments to reconcile net loss to cash used in operating activities:  
Depreciation and amortization108 91 
Change in fair value of warrants 957 
Loan forgiveness income (Note 9) (333)
Loss on disposal of fixed assets 206 
Charge for 401(k) company common stock match69 66 
Stock-based compensation739 297 
Non-cash lease expense175 262 
Deferred income tax provision14 27 
Changes in operating assets and liabilities:  
Accounts receivable10 59 
Unbilled receivables(11)(39)
Prepaid expenses and other assets24 84 
Accounts payable41 (129)
Accrued expenses(69)(390)
Lease liabilities(220)(391)
Other liabilities(3)17 
Net cash used for operating activities(4,776)(4,612)
Cash flows from investing activities  
Purchase of property and equipment(136)(42)
Proceeds from sale of property and equipment 10 
Purchase of investments(3,891)(503)
Proceeds from the maturity of short-term investments5,250 999 
Net cash provided by investing activities1,223 464 
Cash flows from financing activities  
Proceeds from warrants exercised (Note 12)3,856 1,658 
Proceeds from PPP loan (Note 9) 333 
Proceeds from public offering, net of issuance costs11,993  
Taxes paid on employees' behalf related to vesting of stock awards(83) 
Net cash provided by financing activities15,766 1,991 
Effect of exchange rate changes on cash, cash equivalents and restricted cash5 (48)
Net increase (decrease) in cash, cash equivalents and restricted cash12,218 (2,205)
Cash, cash equivalents and restricted cash at beginning of period3,687 5,749 
Cash, cash equivalents and restricted cash at end of period$15,905 $3,544 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
6


YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF SERIES B CONVERTIBLE STOCK AND STOCKHOLDERS' EQUITY
UNAUDITED
(In thousands, except share amounts)

Three Months Ended June 30, 2021
Series B Convertible Preferred StockSeries A Convertible Preferred StockCommon StockAdditional Paid-In CapitalAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
SharesPar ValueSharesPar ValueSharesPar ValueAccumulated Deficit
Balance, March 31, 2021 $  $ 4,865,335 $49 $400,865 $(159)$(377,661)$23,094 
Non-cash stock-based compensation expense— — — — — — 414 — — 414 
Issuance of common stock for 401(k) match— — — — 3,131 — 40 — — 40 
Effect of foreign currency translation and unrealized loss on investments— — — — — — — 6 — 6 
Net loss— — — — — — — — (3,092)(3,092)
Balance, June 30, 2021 $  $ 4,868,466 $49 $401,319 $(153)$(380,753)$20,462 

Three Months Ended June 30, 2020
Series B Convertible Preferred StockSeries A Convertible Preferred StockCommon StockAdditional Paid-In CapitalAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
SharesPar ValueSharesPar ValueSharesPar ValueAccumulated Deficit
Balance, March 31, 2020 $ 296 $ 1,923,184 $19 $377,963 $(159)$(368,494)$9,329 
Non-cash stock-based compensation expense— — — — — — 194 — — 194 
Issuance of common stock for 401(k) match— — — — 10,114 — 38 — — 38 
Issuance of common stock for warrant exercise— — — — 2,500  730 — — 730 
Issuance of common stock upon conversion of Series A Convertible Preferred Stock— — (296)— 37,000 1 (1)— — — 
Effect of foreign currency translation and unrealized loss on investments— — — — — — — (8)— (8)
Net loss— — — — — — — — (1,796)(1,796)
Balance, June 30, 2020 $  $ 1,972,798 $20 $378,924 $(167)$(370,290)$8,487 
7


Six Months Ended June 30, 2021
Series B Convertible Preferred StockSeries A Convertible Preferred StockCommon StockAdditional Paid-In CapitalAccumulated other Comprehensive LossAccumulated DeficitTotal Stockholders' Equity
SharesPar ValueSharesPar ValueSharesPar Value
Balance, December 31, 2020 $  $ 3,334,048 $33 $384,758 $(159)$(375,100)$9,532 
Non-cash stock-based compensation expense— — — — — — 749 — — 749 
Issuance of common stock for 401(k) match— — — — 6,890 — 62 — — 62 
Issuance of common stock for warrant exercise— — — — 481,973 5 3,851 — — 3,856 
Issuance of common stock for restricted stock units— — — — 5,555 —  — —  
Taxes paid on employees' behalf related to vesting of stock awards— — — — — — (83)— — (83)
Issuance of common stock in connection with stock offering, net of offering costs— — — — 1,040,000 11 11,982 — — 11,993 
Effect of foreign currency translation and unrealized loss on investments— — — — — — — 6 — 6 
Net loss— — — — — — — — (5,653)(5,653)
Balance, June 30, 2021 $  $ 4,868,466 $49 $401,319 $(153)$(380,753)$20,462 
Six Months Ended June 30, 2020
Series B Convertible Preferred StockSeries A Convertible Preferred StockCommon StockAdditional Paid-In CapitalAccumulated other Comprehensive LossAccumulated DeficitTotal Stockholders' Equity
SharesPar ValueSharesPar ValueSharesPar Value
December 31, 20195,750 $ 796 $ 933,423 $9 $360,926 $(126)$(364,894)$(4,085)
Non-cash stock-based compensation expense— — — — — — 354 — — 354 
Issuance of common stock for 401(k) match— — — — 13,829 — 63 — — 63 
Issuance of common stock for warrant exercise— — — — 207,296 2 1,656 — — 1,658 
Issuance of common stock upon conversion of Series A Convertible Preferred Stock— — (796)— 99,500 2 (2)— — — 
Issuance of common stock upon conversion of Series B Convertible Preferred Stock(5,750)— — — 718,750 7 (7)— — — 
Reclassification of warrant liability to equity— — — — — — 15,934 — — 15,934 
Effect of foreign currency translation and unrealized loss on investments— — — — — — — (41)— (41)
Net loss— — — — — — — — (5,396)(5,396)
Balance, June 30, 2020 $  $ 1,972,798 $20 $378,924 $(167)$(370,290)$8,487 
The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements
8


YIELD10 BIOSCIENCE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
UNAUDITED

(All dollar amounts, except share and per share amounts, are stated in thousands)
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
    Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the "Trait Factory", to develop improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada. The Company's goals are to efficiently develop and commercialize a high value crop products business by developing superior varieties of Camelina for the production of feedstock oils and meal, nutritional oils, and PHA bioplastics, and to license its yield traits to major seed companies for commercialization in major row crops, including corn, soybean and canola.
    The accompanying condensed consolidated financial statements are presented in U.S. dollars, are unaudited, and have been prepared by Yield10 in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for fair statements of the financial position and results of operations for the interim periods ended June 30, 2021 and June 30, 2020.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 16, 2021.
The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including the three and six months ended June 30, 2021.
    As of June 30, 2021, the Company held unrestricted cash, cash equivalents and investments of $20,562. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. Based on its current cash forecast, management expects that the Company's present capital resources will be sufficient to fund its planned operations for at least that period of time. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional government grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management may be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down its operations and pursue options for liquidating its remaining assets, including intellectual property.
    If the Company issues equity or debt securities to raise additional funds in the future, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.
9


The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain. While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the evolving nature of the COVID-19 pandemic and the global responses to it, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for future periods.
2. ACCOUNTING POLICIES
Principles of Consolidation
The Company's unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, Metabolix Oilseeds, Inc. ("MOI") and Yield10 Bioscience Securities Corp.
Reverse Stock Split
    On January 15, 2020, the Company effected a 1-for-40 reverse stock split of its common stock. Unless otherwise indicated, all share amounts, per share data, share prices, and conversion rates set forth in these notes and the accompanying unaudited condensed financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Unaudited Condensed Consolidated Balance Sheets included herein:
June 30,
2021
December 31,
2020
Cash and cash equivalents$15,641 $3,423 
Restricted cash264 264 
Total cash, cash equivalents and restricted cash$15,905 $3,687 
Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $264 at June 30, 2021 and December 31, 2020 consists primarily of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.
Investments
The Company classifies investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. The Company classifies investments with a maturity date of greater than one year from the balance sheet date as long-term investments.
Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.
10


Foreign Currency Translation
The functional currency for MOI is the Canadian dollar. Foreign denominated assets and liabilities of MOI are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells all or substantially all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.
Comprehensive Loss
Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.
Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.
The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.
At June 30, 2021, 100% of the Company's accounts and unbilled receivables are due from the Company's Michigan State University ("MSU") sub-award. During the three and six months ended June 30, 2021, revenue earned from the MSU sub-award, represented 100.0% and 89.5% of recognized government grant revenue, respectively. A research grant of $39 awarded to MOI through the Canadian Industrial Research Assistance Program ("IRAP") and earned during the first quarter of 2021, represented the remaining difference of 10.5% during six months ended June 30, 2021. During the three and six months ended June 30, 2020, the MSU sub-award represented 69.7% and 83.3%, of government grant revenue earned for each of the respective periods. The remaining differences of 30.3% and 16.7% during the three and six months ended June 30, 2020 were from grant revenue recognized from an earlier Canadian research grant of $67 awarded through IRAP.

Fair Value Measurements
The carrying amounts of the Company's financial instruments as of June 30, 2021 and December 31, 2020, which include cash equivalents, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 5 for further discussion on fair value measurements.
11


Segment Information
The accounting guidance for segment reporting establishes standards for reporting information on operating segments in financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of improved Camelina varieties to produce proprietary products, and to produce other high value genetic traits for the agriculture and food industries. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:
Asset DescriptionEstimated Useful Life (years)
Equipment3
Furniture and fixtures5
Software3
Leasehold improvementsShorter of useful life or term of lease
Right-of-Use Assets
The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, ("ASC 842") which requires lessees to recognize a lease liability and a corresponding right-of-use asset for long-term lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The Company uses its incremental borrowing rate in calculating the present value of future lease payments when interest rates are not implicit in the lease. Leases with terms of 12 months or less at inception are expensed as costs are incurred and not capitalized under ASC 842.
Impairment of Long-Lived Assets
Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.
Grant Revenue
The Company's source of continuing revenue is from its government research grants, in which it serves as either the primary contractor or as a subcontractor. These grants are considered a central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying unaudited condensed consolidated balance sheets at June 30, 2021 and December 31, 2020. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.
Research and Development
All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation. Costs incurred in connection with government research grants are recorded as research and development expense.
General and Administrative Expenses
The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation, stock-based compensation and office related expenses incurred to support the administrative and business development operations of the Company.
12


Intellectual Property Costs
The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the Company's unaudited condensed consolidated statement of operations.
Stock-Based Compensation
All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expenses based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 7 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.
Recent Accounting Standards
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. During the three months ended June 30, 2021, the Company did not adopt any new accounting guidance.
In December 2019 the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our consolidated financial statements and related disclosures.
The following new pronouncement is not yet effective but may impact the Company's financial statements in the future.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
3. BASIC AND DILUTED NET INCOME (LOSS) PER SHARE
Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units and the conversion of convertible preferred stock. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.
The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units, convertible preferred stock and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three and six months ended June 30, 2021 and June 30, 2020, respectively, are shown below. Issued and outstanding warrants and more detailed information related to the Company's convertible preferred stock shown in the table below are described in greater detail in Note 12, contained herein.
13


Three Months Ended
June 30,
Six Months Ended
   June 30,
 2021202020212020
Options198,907 71,873 177,595 69,852 
Restricted Stock Awards18,862 17,000 14,639 13,170 
Series A Convertible Preferred Stock 12,166  25,613 
Series B Convertible Preferred Stock   63,187 
Warrants175,995 2,843,699 175,955 2,843,699 
Total393,764 2,944,738 368,189 3,015,521 

4. INVESTMENTS
Investments consist of the following at June 30, 2021 and December 31, 2020:
Accumulated Cost at June 30, 2021UnrealizedMarket Value at June 30, 2021
Gain(Loss)
Short-term investments
     U.S. government and agency securities$4,920 $1 $ $4,921 
          Total$4,920 $1 $ $4,921 
Accumulated Cost at December 31, 2020UnrealizedMarket Value at December 31, 2020
Gain(Loss)
Short-term investments
     U.S. government and agency securities$6,279 $ $ $6,279 
          Total$6,279 $ $ $6,279 
All investments are classified as available for sale as of June 30, 2021 and December 31, 2020.
5. FAIR VALUE MEASUREMENTS
The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.
The Company’s financial assets classified as Level 2 at June 30, 2021 and December 31, 2020 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of June 30, 2021 and December 31, 2020.
The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.
14


Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets
Significant other
observable inputs
Significant
unobservable  inputs
Balance as of
Description(Level 1)(Level 2)(Level 3)June 30, 2021
Assets
Cash equivalents:
Money market funds
$14,132 $ $ $14,132 
Short-term investments:
U.S. government and agency securities
 4,921  4,921 
Total assets$14,132 $4,921 $ $19,053 

Fair value measurements at reporting date using
Quoted prices in active markets for  identical
assets
Significant other
observable inputs
Significant
unobservable  inputs
Balance as of
Description(Level 1)(Level 2)(Level 3)December 31, 2020
Assets
Cash equivalents:
Money market funds
$2,873 $ $ $2,873 
Short-term investments:
U.S. government and agency securities
 6,279  6,279 
Total assets$2,873 $6,279 $ $9,152 
There were no transfers of financial assets or liabilities between category levels during the three and six months ended June 30, 2021 and the three and six months ended June 30, 2020.
During November 2019, the Company issued Series A Warrants and Series B Warrants in two concurrent securities offerings that were considered free standing financial instruments, that were legally detachable and separately exercisable from the common and preferred stock issued in the two offerings. The Company initially determined that all of the Series A Warrants and Series B Warrants should be classified as a warrant liability in accordance with ASC 480, Distinguishing Liabilities from Equity, and recognized at their inception date fair value due to the insufficiency of common shares available to permit their exercise. The warrant liability met Level 3 classification criteria for classification within the fair value hierarchy. On January 15, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to effect a 1-for-40 reverse stock split. As a result of the reverse stock split, the Company's number of authorized but unissued shares of Common Stock increased significantly and the Series A Warrants and Series B Warrants became eligible for exercise. Prior to reclassification as equity, on January 15, 2020, the Company adjusted the warrant liability to its then $15,934 fair value using the Black-Scholes valuation model, recording a loss on the adjustment to fair value of $957.
The following table shows a reconciliation of the beginning and ending balances for the Level 3 warrant liability for the six months ending June 30, 2020.
Six Months Ended June 30, 2020
Warrant liability, December 31, 2019$14,977 
Recognized loss from mark-to-market adjustment prior to reclassification of warrant liability to equity957 
Reclassification from warrant liability to equity(15,934)
Warrant liability, June 30, 2020$ 
15


6. ACCRUED EXPENSES
Accrued expenses consisted of the following at:
June 30,
2021
December 31,
2020
Employee compensation and benefits$575 $620 
Leased facilities52 188 
Professional services263 235 
Field trials and related expenses186 52 
Other161 202 
Total accrued expenses$1,237 $1,297 

7. STOCK-BASED COMPENSATION
Expense Information for Employee and Non-Employee Stock Awards
The Company recognized stock-based compensation expense related to stock awards, including awards to non-employees and members of the Board of Directors of $415 and $739 for the three and six months ended June 30, 2021 and $160 and $297 for the three and six months ended June 30, 2020, respectively. At June 30, 2021, there was approximately $3,915 of pre-tax stock-based compensation expense related to unvested awards not yet recognized.
The compensation expense related to unvested stock awards is expected to be recognized over a remaining weighted average period of 3.11 years.
Stock Options
A summary of option activity for the six months ended June 30, 2021 is as follows:
Number of
Shares
Weighted Average
Exercise Price
Outstanding at December 31, 2020339,108 $32.39 
Granted192,875 $13.93 
Exercised $ 
Forfeited $ 
Expired(37)$19,253.19 
Outstanding at June 30, 2021531,946 $24.36 
Options exercisable at June 30, 2021135,785 $63.01 
In accordance with the terms of the Company's 2018 Stock Option and Incentive Plan ("2018 Stock Plan"), effective January 1, 2021, Yield10's Board of Directors approved the addition of 166,702 shares to the 2018 Stock Plan, which represented 5% of the Company's outstanding common stock on the day prior to the increase. At its annual meeting of stockholders on May 24, 2021, stockholders approved an amendment to the 2018 Stock Plan to add 300,000 more shares to the plan. As of June 30, 2021, 258,186 shares remain available to be awarded from the 2018 Plan.
Restricted Stock Units
The Company records stock compensation expense for restricted stock units ("RSUs") on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date market value. As RSUs vest, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount from the common stock issuable at the vest date. During the six months ended June 30, 2021, 8,500 employee RSUs vested, of which 2,945 common shares with a total market value of $67 were withheld to pay employee tax withholding.
16


A summary of RSU activity for the six months ended June 30, 2021 is as follows:
Number of RSUsWeighted Average Remaining Contractual Life (years)
Outstanding at December 31, 20208,500 
Awarded18,862 
Common stock issued upon vesting(8,500)
Forfeited 
Outstanding at June 30, 202118,862 0.42

8. LEASES
Lease Accounting
As a lessee, the Company follows the lease accounting guidance codified in ASC 842. Under ASC 842, a lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease. Any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. The Company's existing lease subject to ASC 842 meets the standards for operating lease classification.
Under ASC 842, a lease liability is recorded on the commencement date of a lease and is calculated as the present value of the remaining lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the lessee's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.
Maturity Analysis of Lease Liabilities
The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities. No other active real estate or equipment leases fall within the scope of ASC 842. At June 30, 2021, the Company's lease liability related to its Woburn facility will mature as follows:
Year ended December 31,Undiscounted Cash Flows
2021 (July to December)$357 
2022726 
2023749 
2024771 
2025793 
Thereafter747 
Total undiscounted future lease payments4,143 
Amount of lease payments representing interest(743)
Total lease liabilities$3,400 
     Short-term lease liability$485 
     Long-term lease liability$2,915 
17


Quantitative Disclosure of Lease Costs
Three Months Ended
   June 30,
Six Months Ended
  June 30,
2021202020212020
Lease cost:
Operating lease cost$151 $183 $303 $386 
Short-term lease cost169 123 326 306 
Sublease income(146)(142)(320)(279)
Total lease cost, net$174 $164 $309 $413 
Other information as of:June 30, 2021December 31, 2020
Weighted-average remaining lease term (years)5.45.9
Weighted-average discount rate7.25%7.25%
Real Estate Leases
    During 2016, the Company entered into a lease agreement, as amended, for its headquarters pursuant to which the Company leases 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease agreement will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain pro rata taxes and operating costs associated with the premises throughout the term of the lease. During the initial buildout of the rented space, the landlord paid for certain tenant improvements that resulted in increased rental payments by the Company. As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset. The Company has provided the landlord with a security deposit of $229.
In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The sublease space was determined to be in excess of the Company's needs. The CJ sublease is coterminous with the Company's master lease and CJ will pay rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $4,143 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.
Through May 2020, the Company leased approximately 13,702 square feet of office and laboratory space in Lowell, Massachusetts. The lease terminated in accordance with the terms of the lease agreement and the facility has been returned to the landlord. No further expenses are anticipated under this lease.
The Company's wholly-owned subsidiary, MOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 7,733 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. MOI's leases for these facilities expire on various dates through May 2022.
9. CARES ACT LOAN
During April 2020, the Company received $333 in loan proceeds through the Paycheck Protection Program Flexibility Act ("PPP"), established pursuant to the CARES Act. Under the CARES Act and the PPP, a borrower could apply for and be granted forgiveness for all or a part of its PPP loan. The amount of loan proceeds eligible for forgiveness was based on a formula that took into account a number of factors, including the amount of loan proceeds used by the borrower during the twenty-four-week period after the loan origination for certain purposes including payroll costs, rent payments on certain leases, and certain qualified utility payments. During the three months ended June 30, 2020, Yield10 utilized the entire PPP Loan amount for qualifying expenses and management of the Company considered it reasonably certain that it would meet the conditions for loan forgiveness. As such, the Company recorded the full amount of the loan, or $333, within other income (expense) in its condensed consolidated statement of operations for the three and six months ended June 30, 2020. The Company received a favorable determination to its application for loan forgiveness in November 2020 for the full amount of the loan.
18


10. COMMITMENTS AND CONTINGENCIES
Contractual Commitments    
Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted")
On November 12, 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted’s program to develop omega-3 oils in Camelina sativa. Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further DHA+EPA trait improvement, field testing and nutritional studies. The Company will pay Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $188 remains outstanding as of June 30, 2021. As part of the agreement, the Company has an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology. The current agreement terminates automatically on its second anniversary unless terminated earlier in accordance with the terms of the agreement.
License Agreement with the University of Massachusetts ("UMASS")
Pursuant to a license agreement with UMASS dated as of June 30, 2015 and subsequently amended, the Company has an exclusive, worldwide license under certain patents and patent applications, including issued patents covering the Company's yield trait gene C3003, relating to the manufacture of plants with enhanced photosynthesis. The agreement provides an exclusive, worldwide license to make, have made, use, offer for sale and import any transgenic plant seed or plant grown from transgenic plant material for sale to a farmer or grower that is derived from (in whole or in part) one or more issued or pending claims of the licensed patents or patent applications.
Pursuant to the UMASS license agreement, the Company is required to use diligent efforts to develop licensed products throughout the field of use and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the agreement would give UMASS the right to termi